Regulus

Type: Keyphrase
Name: Regulus
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Christopher James Turns a Clinical Eye on Biotechs with High Reward Potential

A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand, recommends that investors willing to diversify their holdings ... [Published Stockboard Media Inc. - Aug 01 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Regulus Receives Orphan Drug Designation For RG-012, A microRNA Therapeutic For The Treatment Of Alport Syndrome

La Jolla San Diego, CA /PRNewswire/ - . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the U.S. Food & Drug Administration (FDA) has granted orphan drug ... [Published Drug Discovery Online - Jul 31 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 2 reports

Regulus Resources : and Southern Legacy Announce Signing of Arrangement Agreement

) - Regulus Resources Inc. ("Regulus") (TSX VENTURE:REG) and Southern Legacy Minerals Inc. ( "Southern Legacy") (TSX VENTURE:LCY) are pleased to announce that further to their press release dated May 20, 2014 , they have executed a definitive arrangement ... [Published 4 Traders - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

US Federal Business Opportunity: Other Defense Agencies: Instrumented Cylinder Head Test Equipment

Agency: Other Defense AgenciesOffice: U.S. Special Operations Command Location: Naval Special Warfare Development GroupDate you need to respond by: 7-July-2014Solicitation Number: H92244-14-T-0264 Naics code: 334519 Computer and Electronic Product M ... [Published ITbriefing - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Regulus Gains Orphan Drug Designation for microRNA Treatment

A recent press release  by the company Regulus Therapeutics highlights their newest orphan drug RG-012 – a microRNA treatment designed to help patients with Alport Syndrome, a life-threatening genetic kidney disease that impacts the body’s ability to ... [Published Terrapinn - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Regulus Receives FDA Orphan Status For Rare Kidney Disease Drug

By Estel Grace MasangkayBiopharmaceutical company Regulus Therapeutics announced that the U.S. Food and Drug Administration (FDA) have issued Orphan Drug designation to its RG-012 for the treatment of rare kidney disease Alport syndrome.RG-012 is being ... [Published Bioresearch Online - Jul 23 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 7 reports

Regulus gets FDA orphan drug status for RG-012 to treat Alport Syndrome

US-based biopharmaceutical firm Regulus Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for RG-012, a single stranded, chemically modified oligonucleotide. ... [Published PBR - News - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 2 reports

Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome

LA JOLLA, Calif."We are pleased to have received orphan drug designation for RG-012 and are encouraged by the FDA's recognition for the need of innovative new treatments like microRNA therapeutics for rare and orphan diseases such as Alport syndrome," ... [Published Bio-Medicine - Jul 21 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Orphan Drug status for Regulus kidney disease therapeutic candidate

11:19 ET | About: Regulus Therapeutics (RGLS)The FDA designates Regulus Therapeutics' (RGLS +3%) miR-21 inhibitor RG-012 an Orphan Drug for the treatment of Alport syndrome. miR-21 is a 22-mer non-coding RNA that is up-regulated in fibrotic kidney disease. ... [Published Seeking Alpha - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Thoma-Sea launches newbuild for GulfMark

| More Thoma-Sea Shipbuilders recently launched Regulus, a DP 2, FiFi I offshore supply vessel from its Houma shipyard.The 272ft OSV was built to service deep water oil and gas exploration. The vessel has two 2,000kW Z-drives and two 850kW bow thrusters ... [Published Offshore Shipping Online - Jul 18 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Berko: The skinny on convertible bonds

Dear Mr. Berko:Please tell me what a convertible bond is and why so few brokers recommend convertible bonds. I’d like to invest a portion of my portfolio in convertible bonds but don’t know where to find research on these strange securities. What do you ... [Published Des Moines Business Record - Jul 11 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 2 reports

General Public to Vote for Exoplanet Names

Naming something can be so much fun but this fun surely increases if someone is a part of the amateur astronomy group and can help bestow names on exoplanets. Also, 305 exoplanets have been opened by the International Astronomical Union for public to ... [Published French Tribune - Jul 10 2014]
Entities: Exoplanet, Arabic, Fomalhaut

Quotes

"We are very excited aboutRexahn Pharmaceuticals Inc.; it's an early-stage oncology company with multiple shots on goal."
...like microRNA therapeutics for rare and orphan diseases such as Alport syndrome," said Paul Grint, M D , Chief Medical Officer of Regulus. "Alport syndrome is a life threatening disease and patients have very limited treatment options because there is currently no approved therapy. We believe that RG-012 represents an opportunity to make a significant impact in the lives of patients with Alport syndrome and we look forward to advancing this program into the clinic."
...are pleased to announce that further to their press release dated May 20, 2014, they have executed a definitive arrangement agreement (the " Agreement ") on July 29, 2014 pursuant to which the two companies will amalgamate. "
"Adjust Your Child Birth Date to August 18 - on Conjunction of Jupiter and Venus"

More Content

All (105) | News (70) | Reports (0) | Blogs (33) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
Battle to be New Zealand's leading 3 year old sire [Published Harnesslink - 14 mins ago]
Christopher James Turns a Clinical Eye on Biote... [Published Stockboard Media Inc. - Aug 01 2014]
Regulus Receives Orphan Drug Designation For RG... [Published Drug Discovery Online - Jul 31 2014]
Regulus Announces Timing for Second Quarter 201... [Published 14 WFIE - Jul 30 2014]
Regulus Announces Timing for Second Quarter 201... [Published PR Newswire: Health - Jul 30 2014]
Regulus Resources : and Southern Legacy Announc... [Published 4 Traders - Jul 29 2014]
Regulus and Southern Legacy Announce Signing of... [Published Marketwire - Breaking News Releases - Jul 29 2014]
Latin American exploration, particularly Chile,... [Published International Mining - Jul 28 2014]
Southern Cross Stargazer for July 27-Aug. 2, 2014 [Published Miami Herald - Jul 26 2014]
US Federal Business Opportunity: Other Defense ... [Published ITbriefing - Jul 25 2014]
Regulus Gains Orphan Drug Designation for micro... [Published Terrapinn - Jul 24 2014]
Regulus Receives FDA Orphan Status For Rare Kid... [Published Bioresearch Online - Jul 23 2014]
Regulus gets FDA orphan drug status for RG-012 ... [Published PBR - News - Jul 22 2014]
Happy Birthday, Prince George! the Royal Baby T... [Published Yahoo! Shine - Jul 21 2014]
Regulus Receives FDA Orphan Drug Designation fo... [Published PharmaceuticalProcessing - Jul 21 2014]
Regulus Gets Orphan Drug Designation For RG-012... [Published RTTNews.com - Jul 21 2014]
Regulus Receives Orphan Drug Designation for RG... [Published Bio-Medicine - Jul 21 2014]
Regulus Therapeutics Inc receives orphan drug d... [Published Reuters - Jul 21 2014]
Regulus Therapeutics granted orphan drug design... [Published Yahoo! Finance - Jul 21 2014]
Regulus Receives Orphan Drug Designation for RG... [Published Wall Street Select - Jul 21 2014]
Regulus Receives Orphan Drug Designation for RG... [Published ADVFN India - Jul 21 2014]
Regulus Receives Orphan Drug Designation for RG... [Published PR Newswire: Policy & Public Interest - Jul 21 2014]
US Federal Business Opportunity: Department of ... [Published ITbriefing - Jul 19 2014]
US Federal Business Opportunity: Other Defense ... [Published ITbriefing - Jul 19 2014]
Orphan Drug status for Regulus kidney disease t... [Published Seeking Alpha - Jul 18 2014]
Thoma-Sea launches newbuild for GulfMark [Published Offshore Shipping Online - Jul 18 2014]
"Adjust Your Child Birth Date to August 18 - on... [Published SBWire - Jul 15 2014]
TerraForm Power S-1 Teardown: Is SunEdison Guil... [Published Seeking Alpha - Jul 15 2014]
Movers and Shakers July 2014 [Published PM 360 - Jul 11 2014]
US Federal Business Opportunity: Department of ... [Published ITbriefing - Jul 11 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Regulus Announces Timing for Second Quarter 201... [Published PR Newswire: Health - Jul 30 2014]
LA JOLLA, Calif., July 30, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results ...
Regulus and Southern Legacy Announce Signing of... [Published Marketwire - Breaking News Releases - Jul 29 2014]
CALGARY, ALBERTA--(Marketwired - July 29, 2014) - Regulus Resources Inc. ("Regulus") (TSX VENTURE:REG) and Southern Legacy Minerals Inc . ("Southern Legacy") (TSX VENTURE:LCY) are pleased to announce that further to their press release dated ...
Regulus gets FDA orphan drug status for RG-012 ... [Published PBR - News - Jul 22 2014]
US-based biopharmaceutical firm Regulus Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for RG-012, a single stranded, chemically modified oligonucleotide. ...
Regulus Receives Orphan Drug Designation for RG... [Published PR Newswire: Policy & Public Interest - Jul 21 2014]
LA JOLLA, Calif., July 21, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the U.S. Food & Drug Administration ...
Regulus Announces Patent Grant from U.S. Patent... [Published PR Newswire: Policy & Public Interest - Jun 25 2014]
LA JOLLA, Calif., June 25, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the U.S. Patent and Trademark ...
1 2 3 4 5 6 7

Press Releases

sort by: Date | Relevance
Regulus Renews Strategic Alliance with Sanofi t... [Published Financial Services - Feb 05 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.